Filing summary: Theravance, Inc. Form 10-Q, quarter ended September 30, 2012
Entity mismatch: The supplied filing identifies the registrant as Theravance, Inc., not Innoviva, Inc. Confirm that this is the intended filing before relying on the figures below.
Business context and reporting period
Theravance was a biopharmaceutical company developing small-molecule medicines in respiratory disease, bacterial infections, and CNS/pain, with major programs partnered with GlaxoSmithKline (GSK). This unaudited 10-Q covers the third quarter and first nine months of 2012, compared with the corresponding 2011 periods.
Financial results and liquidity
| Metric | Q3 2012 | Q3 2011 | Nine months 2012 | Nine months 2011 |
|---|---|---|---|---|
| Revenue | $1.4 million | $6.4 million | $130.0 million | $19.2 million |
| Research and development expense | $27.0 million | $27.8 million | $89.8 million | $71.1 million |
| General and administrative expense | $7.8 million | $7.8 million | $23.2 million | $22.2 million |
| Operating income (loss) | ($33.4 million) | ($29.2 million) | $17.0 million | ($74.2 million) |
| Net income (loss) | ($34.7 million) | ($30.6 million) | $12.8 million | ($78.3 million) |
- Nine-month 2012 revenue and profit included $125.8 million of deferred Astellas collaboration revenue recognized after Astellas terminated the VIBATIV agreement in January 2012. The reported nine-month profit therefore does not indicate recurring operating profitability.
- Q3 revenue fell 78% year over year; nine-month revenue rose 577%, largely because of that one-time accelerated recognition. Q3 net loss increased about 13%.
- Cash and cash equivalents were $112.2 million at September 30, 2012; short-term investments were $161.2 million and long-term marketable securities were $89.0 million. Together these totaled $362.4 million, excluding $0.8 million of restricted cash.
- Operating cash use was $103.3 million in the first nine months, versus $63.0 million a year earlier. Investing cash use was $58.4 million; financing provided $229.1 million, mainly from GSK’s share purchase.
- Current assets were $282.5 million and current liabilities $27.1 million. Convertible subordinated notes had $172.5 million principal outstanding, bearing 3% interest and due January 2015; their reported fair value was $206.4 million.
- Stockholders’ equity was $173.3 million at September 30, compared with a net capital deficiency of $87.1 million at December 31, 2011. Common shares outstanding rose from 85.5 million to 97.9 million, principally reflecting equity issuance.
Material changes and management commentary
- GSK invested $212.9 million in 10.0 million shares in May 2012; net proceeds from the placement were reported as $212.5 million. Additional GSK top-up purchases provided $8.9 million in August.
- R&D expense rose 26% for the nine-month period, mainly due to TD-1211 Phase 2 work, discovery programs, and higher employee costs. Management expected 2012 R&D expense to exceed 2011 levels.
- Management expected 2012 G&A expense to increase slightly year over year, partly because Theravance assumed VIBATIV-related activities previously handled under the Astellas collaboration.
- Management said available cash, cash equivalents, and marketable securities were expected to fund anticipated operating needs for at least the next 12 months, based on current plans and assumptions. Additional financing could be needed sooner if plans, forecasts, or spending change.
- The company had no reported off-balance-sheet financial arrangements. Potential LABA collaboration milestone payments to GSK could total up to $220 million if specified products launch in multiple regions; no liability had been recorded for these contingent payments.
Outlook, risks, contingencies, and unusual items
- FF/VI COPD filings were under review in the United States and Europe; the U.S. FDA goal date was May 12, 2013. GSK completed the UMEC/VI Phase 3 program and planned regulatory submissions from late 2012. Both programs remained subject to regulatory and safety uncertainties.
- VIBATIV faced critical supply shortages and regional outages following manufacturing problems at its single-source supplier. The European marketing authorization had been suspended; replacement manufacturing at Hospira required regulatory approval, potentially through mid-2013. An FDA advisory committee was scheduled to discuss the nosocomial-pneumonia application in November 2012.
- Astellas terminated the VIBATIV collaboration, leaving Theravance responsible for assessing commercialization options and certain product-related costs. Theravance had purchased $4.3 million of VIBATIV active ingredient and raw materials under agreements allowing purchases of up to $6.2 million of raw materials and $4.2 million of finished goods, subject to release.
- Key risks included clinical-trial failure or delay, regulatory non-approval, manufacturing and supply constraints, dependence on partners, competition, need for future funding, and potential dilution. The company reported an accumulated deficit of approximately $1.3 billion and expected substantial ongoing losses.
- Subsequent to quarter-end, Theravance signed agreements with Alfa Wassermann for velusetrag, Merck for cardiovascular-target research, and R-Pharm for TD-1792 and telavancin. Disclosed potential payments were contingent on options, development, regulatory, or sales outcomes and were not current-period revenue.
- Management concluded disclosure controls were effective as of September 30, 2012; it reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the registrant and filing are intended: the supplied document is for Theravance, Inc., although the request names Innoviva, Inc.
- Separate recurring collaboration economics from the $125.8 million Astellas deferred-revenue recognition when assessing earnings and revenue trends.
- Track operating cash burn against the stated 12-month liquidity outlook, and evaluate the effect of any self-funded Phase 3 development or commercialization spending.
- Verify the progress and regulatory outcomes for FF/VI and UMEC/VI, and the status of VIBATIV manufacturing, supply, and regulatory matters.
- Assess the 2015 note maturity, potential GSK milestone obligations of up to $220 million, GSK ownership and governance rights, and the dilution from the 2012 share issuance.